PAVmed Q2 2026 net loss $5.5M; Lucid EsoGuard revenue $1.5M, cash up to $3.8M

PAVmed Inc.

2026-Q2 EPS reported -$3.17 revenue$55,000

Q2 2026 GAAP net loss ~$5.5M ($0.87/diluted share); non-GAAP adjusted net loss ~$1.7M ($0.27/share).
Cash and equivalents $3.8M at June 30, 2026, up from $1.5M at Dec 31, 2025; operating expenses ~$7.1M.
Lucid Diagnostics (LUCD) posted $1.5M EsoGuard revenue in 2Q26, 2,770 tests; secured first lab benefit manager coverage policy.
Veris Health accelerated commercial engagement with OSU-The James; implantable monitor on track for early 2027 FDA 510(k) submission.
PortIO first-in-human data published in Journal of Vascular Access: 100% patency, 90% intended implant duration completion, no device-related adverse events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.